Suppression of melanoma-associated neoangiogenesis by bevacizumab

Archives of Dermatology

Volumn 144, Issue 4, 2008, Pages 525-527

  Jaissle, Gesine B ^a   Ulmer, Anja ^b   Henke Fahle, Sigrid ^a   Fierlbeck, Gerhard ^b   Bartz Schmidt, Karl Ulrich ^a   Szurman, Peter ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN;

AGED; ANAMNESIS; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; DRUG EFFECT; DRUG EFFICACY; EYE CANCER; HUMAN; MALE; MELANOMA; PRIORITY JOURNAL; RETINA TUMOR; VITRECTOMY; VITREOUS BODY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; EYE NEOPLASMS; HUMANS; INJECTIONS, INTRALESIONAL; IRIS NEOPLASMS; MALE; MELANOMA; NEOVASCULARIZATION, PATHOLOGIC; RETINAL NEOPLASMS; RETREATMENT; SKIN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRECTOMY; VITREOUS BODY;

EID: 42549159630     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archdermatol.2007.38     Document Type: Article

References (10)

1. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342.
2. González Cao M, Viteri S, Garran C, et al. Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumab. Clin Transl Oncol. 2007;9(2):119-120.
3. Jaissle GB, Szurman P, Rohrbach JM, et al. A case of cutaneous melanoma metastatic to the vitreous cavity: possible pathomechanism and review of the literature. Graefes Arch Clin Exp Ophthalmol. 2007;245(5):733-740.
4. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3635-3648.
5. Gündüz K, Shields JA, Shields CL, et al. Cutaneous melanoma metastatic to the vitreous cavity. Ophthalmology. 1998;105(4):600-605.
6. Graeven U, Fiedler W, Karpinski S, et al. Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR. J Cancer Res Clin Oncol. 1999;125(11):621-629.
7. Demirkesen C, Büyükpinarbasili N, Ramazanoglu R, et al. The correlation of angiogenesis with metastasis in primary cutaneous melanoma: a comparative analysis of microvessel density, expression of vascular endothelial growth factor and basic fibroblastic growth factor. Pathology. 2006;38(2):132-137.
8. Graells J, Vinyals A, Figueras A, et al. Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. J Invest Dermatol. 2004;123(6):1151-1161.
9. Salven P, Heikkila P, Joensuu H. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br J Cancer. 1997;76(7):930-934.
10. Govindarajan B, Sligh JE, Vincent BJ, et al. Overexpression of Akt converts radial growth melanoma to vertical melanoma. J Clin Invest. 2007;117(3):719-729.